SOHM, Inc., Has Signed Manufacturing and Supply Skincare Topical Products with New Customer.
CHINO HILLS, CA—August 29, 2022 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that the company has signed and received an initial purchase order for development, manufacturing and supply new skincare SKU for its human prescription topical products for its new Southern California based customer.
Today, Mr. Baron Night, CEO, announced that SOHM has been in negotiation with a Southern California-based leading Skincare product distributor for the development, manufacturing, and supply of the client’s proprietary products, and we have now received an initial purchase order for 5000 units of Skincare product. The product is a human prescription product used for skin care, acne care, exfoliation, and anti-aging purposes. These mandates will strengthen the company’s efforts to continue its B2B business under a private label agreement.
This mandate and scope of the project is just the beginning of launching its products to the major dermatologist and plastic surgeons all across the USA and the rest of the world. Our customer has more than 10,000 active dermatologists and plastic surgeons on their customer list, Mr. Night added.
Mr. Night stated that upon executing this purchase order in the next 8 weeks, the company would have more different compositions and SKUs and categories of products, including Cleansers, Creams, and other enhancing skincare products from the new customer. The customer is the pioneer in the Skincare market and has some very good proprietary formulations with them. The company targets to develop at least one to two products every month and finish the development and supply in the next 4 to 5 months.
Mr. Baron Night, CEO, said, “SOHM is very pleased to have received this new account and project. The skin care market is significantly increased in recent past years, and the company aims to capture significant market share through its customers. This initial order represents an annualized commitment once the order is executed and the product is in the hands of “dermatologists and plastic surgeons”.
The management continues and assures that SOHM achieves its target for higher revenue growth in 2022 compared to previous years.
About SOHM, Inc.
SOHM, Inc. is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing targets the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India and strategic alliances with US manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To know more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:
This news release contains “forward-looking statements”, which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
For more information, please contact: